Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 13th. Analysts expect Alpha Tau Medical to post earnings of ($0.12) per share for the quarter.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its earnings results on Monday, May 19th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. On average, analysts expect Alpha Tau Medical to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Alpha Tau Medical Stock Up 3.7%
DRTS stock traded up $0.12 during trading hours on Friday, reaching $3.39. 96,722 shares of the stock were exchanged, compared to its average volume of 46,499. The firm's 50-day moving average is $3.06 and its 200-day moving average is $2.93. The company has a market cap of $287.54 million, a price-to-earnings ratio of -7.37 and a beta of 0.99. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.81 and a quick ratio of 5.81. Alpha Tau Medical has a 12 month low of $2.06 and a 12 month high of $4.39.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and set a $9.00 target price on shares of Alpha Tau Medical in a report on Tuesday, April 29th.
Check Out Our Latest Stock Analysis on DRTS
About Alpha Tau Medical
(
Get Free Report)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Featured Stories

Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.